Singular Genomics Systems, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Singular Genomics Systems, Inc. released its third quarter 2024 results, showing a decrease in revenue and ongoing net losses as the company explores strategic alternatives.
Singular Genomics Systems, Inc. reports a net loss of $46.3 million for the first six months of 2024, while focusing on the development of its G4X spatial sequencer.
Singular Genomics Systems, Inc. reports a net loss of $25.0 million for the first quarter of 2024, with a strategic focus on the development of the G4X spatial sequencer.